The influence of intestinal bacterial decontamination on the occurrence of grades I1 t o IV acute graft-versus-host disease (GVHD) was retrospectively analyzed in 194 predominantly adult patients treated by genotypically identical sibling marrow transplantation under conditions of strict protective isolation and intestinal antimicrobial decontamination. Fortyfive patients (23%) developed acute GVHD and univariate analysis identified four features that significantly increased the risk for this reaction: chronic myeloid leukemia as the underlying disease, as compared with all other disease categories (P < .0001); female marrow donors for male recipients, as compared with other gender combinations (P .005); ineffective, as compared with sustained growth suppression of intestinal anaerobic bacteria (P < .006); and methotrexate as the sole immunprophylactic compound, as compared with cyclosporine containing regimens (P < .05).
The influence of intestinal bacterial decontamination on the occurrence of grades I1 t o IV acute graft-versus-host disease (GVHD) was retrospectively analyzed in 194 predominantly adult patients treated by genotypically identical sibling marrow transplantation under conditions of strict protective isolation and intestinal antimicrobial decontamination. Fortyfive patients (23%) developed acute GVHD and univariate analysis identified four features that significantly increased the risk for this reaction: chronic myeloid leukemia as the underlying disease, as compared with all other disease categories (P < .0001); female marrow donors for male recipients, as compared with other gender combinations (P .005); ineffective, as compared with sustained growth suppression of intestinal anaerobic bacteria (P < .006); and methotrexate as the sole immunprophylactic compound, as compared with cyclosporine containing regimens (P < .05).
Using the duration of anaerobic growth suppression as a time-dependent explanatory variable, proportional hazards regression analysis confirmed these features as independent predictors for acute GVHD with relative risk estimates of 1.9 (95% confidence interval [CI], 1.3 t o 2.7) for the immunprophylactic regimen (P < .0004), of 1.8 (95% CI, 1.3 t o 2.5) for
CUTE GRAFT-VERSUS-HOST disease (GVHD) re-
A mains a leading cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT). It is commonly thought to result from differences between the marrow donor's and recipient's gene products encoded by the human major histocompatibility complex (MHC) and other currently not well-defined polymorphic systems outside the MHC. Besides the outstanding significance of the degree of histoincompatibility, the occurrence of acute GVHD can be modulated by a variety of other factors that have been partially identified by means of retrospective analyses and comparative clinical trials. While the influence of the type of immunpharmacologic prophylaxis, of patient or donor age, and of the state of alloimmunization (by transfusions or pregnancies) of females donating marrow for male recipients on acute GVHD is generally regarded as well-defined, other potential hazards await further confirmati0n. 1-1~ identified the quality of anaerobic decontamination as the third most important predictor for acute GVHD, when all four significant features were included. Estimates of acute GVHD stratified by the quality of anaerobic bacterial growth suppression showed a strong influence of anaerobic decontamination in patients burdened by at least one of the other unfavorable factors (P < .009). In conclusion, this study provides strong evidence that sustained growth suppression of intestinal anaerobic bacteria after clinical sibling marrow transplantation can independently modulate the occurrence of grades II t o IV acute GVHD, which is in concordance with previous results from animal transplantation models. Antimicrobial chemotherapy specifically targeted t o the intestinal anaerobic bacterial microflora may be complementarily useful in preventing acute GVHD and should be investigated in a prospective trial. 0 1992 by The American Society of Hematology.
Studies in germ-free or completely decontaminated rodents showed that the absence or complete elimination of the intestinal microflora prevents the development of delayed-type acute GVHD in recipient animals of MHCmismatched transplant^.^^-^^ In nonhuman primates, complete decontamination was found to be similarly effective in preventing acute GVHD after MHC-mismatched, one-log T-lymphocyte-depleted tran~p1ants.l~
The significance of the intestinal microflora in modulating the occurrence of acute GVHD after human marrow transplantation currently remains controversial. Clinical trials on the role of intestinal decontamination in human marrow transplant recipients led to inconsistent results as a consequence of nonuniform definitions of decontamination efficacy, varying microbiologic techniques for isolation, quantification and differentiation of the intestinal flora, small patient numbers, and differing patient populat i o n~.~~-~~ Furthermore, most of these analyses did not take other potential factors influencing the pathogenesis of acute GVHD into account.
The present report focuses on the association between the suppression of the intestinal bacterial microflora and the risk of acute GVHD after non-T-lymphocyte-depleted HLA-genotypically identical sibling marrow transplantation in a larger single-center patient population.
INTESTINAL ANAEROBIC BACTERIA AND ACUTE GVHD 2669 conditions or because they were unable to tolerate the discomfort inherent in the oral decontamination medication. Another five patients died before hematopoietic engraftment and were therefore considered not evaluable for the development of acute GVHD. The demographic characteristics, underlying diseases, and details of the preparative regimens before marrow transplantation of the remaining fully eligible 194 patients are summarized in Table 1 . Treatment of the patients enrolled in the transplant program followed guidelines approved by the Committee on Treatment of Human Subjects in Research at the University Hospital Essen. Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; SAA, severe aplastic anemia; CR, complete remission; CP, chronic phase: TBI, total body irradiation (single, 1 x 8.6 Gy; fractionated, 4 x 2.5 Gy); Cy, 2 x 60 mg/kg of body weight cyclophosphamide IV (malignant disease), 4 x 50 mglkg of body weight cyclophosphamide IV (nonmalignant disease); BU, 1 mg/kg of body weight busulfan every 6 hours over 4 days orally; TNI, total nodal irradiation (4 x 3.2 Gy); MTX, methotrexate 15 mglm2 of body surface area IV on day 1.10 mg/mz MTX IV on days 3, 6, and 11, and once weekly until day 102;
sMTX, short course of methotrexate (15 mg/m2 of body surface area MTX IV on day 1.10 mg/m2 MTX IV on days 3,6, and 11; CSP, 3 mg/kg cyclosporine as continuous infusion day -1 until day42. *Four patients with myelodysplastic syndromes in leukemic transformation, two patients with acute osteomyelofibrosis, one patient with medulloblastoma, and one patient with multiple myeloma. tlncluding one patient with SAA associated with paroxysmal nocturnal hemoglobinuria.
SFive to 10 mg of murine MoAb directed to the constant part of the cr/p T-lymphocyte receptor IV on days 10 through 19.
Gnotobiotic measures and supportive care. Patients were treated under conditions of strict protective isolation using either downstream laminar air flow systems with air filtration (n = 51) or reverse isolation rooms with conventional air supply (n = 143) as previously described." Assignment of patients to the type of protective environment was based on its availability. Nursing staff, physicians, and other attendants used aseptic techniques with complete surgical dressing during patient contacts throughout the isolation period, which was initiated at least 2 weeks before transplantation and was generally maintained until discharge (usually on day 50 after transplantation [day 0 designates the day of marrow infusion]). With the intention to prevent infections and to attain decontamination of the intestinal microflora, nonabsorbable antibiotic and antimycotic compounds (320 mg gentamycinl tobramycin or 600 mg netilmycin in combination with 2,800 mg amphotericin-B and 5.2 x 1 8 U nystatin) were administered orally in four divided daily doses. The first 22 patients received in addition four daily oral doses of 500 mg cephazolin solution. If analyses of fecal samples indicated colonization of the gastrointestinal tract with bacteria resistent to the decontamination medications, additional treatment with oral or parenteral antibiotics was initiated according to results of sensitivity testings. Isolation and oral decontamination measures were supplemented by daily skin cleansing in a sterile water bath containing 1-propanol, 2-propanol, and 2-biphenylol, disinfection of the oral mucous membranes using polyvinyl-pyrrolidon-iodine solution three times daily, restriction to autoclaved nutrients or sterile beverages, and sterilization of all items introduced into the protective environment.
To prevent pmumocysfis carinii infections, oral trimethoprimsulfamethoxazole was administered over a 2-week period until the day before transplantation. For treatment of suspected or documented bacterial infections, all granulocytopenic patients developing fever greater than 38.5"C received a systemic broad-spectrum antibiotic chemotherapy consisting first-line of an ureido-penicillin in combination with an aminoglycoside and a penicillinaseresistent penicillin. If signs of infection persisted despite adequate antibacterial treatment and a deep or systemic mycotic infection was suspected or documented, intravenous (IV) amphotericin B was additionally instituted. Herpes virus infections were treated with IV acyclovir, which was generally not used for the prevention of endogenous reactivation in seropositive patients. A variety of mostly unsuccessful approaches (eg, high doses of IV acyclovir alone or in combination with hyperimmunglobulines) were used for the treatment of infections with cytomegalovirus (CMV) hefore ganciclovir became available.
During the early posttransplant period, all patients received a regular substitution with platelet concentrates prepared by blood cell separators until self-sustaining platelet counts in excess of 20 x 109/L were reached. If the peripheral blood hemoglobin content declined below 8 g/dL, packed red blood cells were substituted. Since the mid 1980s, blood preparations from CMV antibodynegative blood donors were used for all patients irrespective of their CMV serostatus. All blood products had been y-irradiated immediately before transfusion with 15 to 20 Gy.
Pharmacologic prophylaxis of acute GVHD consisted of IV methotrexate (MTX) according to the standard Seattle protocol in the first 110 patients.25 Seventy-two patients received a regimen with a short course of MTX in combination with continuous intravenous cyclosporine (CSP), as bas been described previously.% CSP alone was used in five patients due to contraindications to MTX. The remaining seven patients received a monoclonal antibody directed to the a/p T-lymphocyte receptor between days 10 and 19 after transplantation in combination with CSP (Table  l) .27, 28 The assessment and grading of acute and chronic GVHD was performed on the basis of clinical findings together with
GVHD.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From histologic evaluation of biopsies from skin, liver, or gastrointestinal tract and followed the commonly accepted criteria proposed by Glucksberg et aIz9 and Thomas et aL30 Starting at admission, samples of oral washings, urine, feces, and swabs from multiple skin sites were obtained at least once weekly for bacterial and mycotic examinations. All fecal samples were regularly cultured for aerobic, microaerophilic, and anaerobic bacteria. Details of the culture techniques used for the present analysis have been p u b l i~h e d .~' .~~ Aerobic cultures were monitored for Escherichia coli and other potential pathogens (including klebsiella, proteus, enterobacter, pseudomonas) as well as for enterococcus, lactobacillus, and staphylococcus species. Samples for anaerobic cultures were immediately processed after collection. These cultures allowed for the detection of different species of the genera bifidobacterium, bacteroides, fusobacterium, clostridium, eubacterium, peptococcus, peptostreptococcus, and veillonella?* Quantitative growth of bacteria was expressed as the common logarithm of colony-forming units (CFU) with a threshold of detection below lo3 CFU per gram of sample. While we were aware of some degree of intersection, we categorized bacteria according to culture growth conditions as either aerobic or anaerobic. Culture proof of any bacterial growth would have classified the respective fecal samples as contaminated.
In patients who later developed acute GVHD, only samples taken before diagnosis of this immunologic reaction were considered eligible for the analysis. The observation period of microbiologic surveillance covered 1 week before and 5 consecutive weeks after transplantation.
The pretransplant serologic status for herpes simplex virus, varicella zoster virus, and CMV of recipients and donors was tested in the vast majority of individuals by enzyme-linked immunosorbent assay (ELSA). In the first 20 donor/recipient combinations, complement fixation assay was exclusively used.
All analyses involving the clinical grades of severity of acute GVHD as an end point were performed on a two-level classification (patients with grades 0-1 versus those with grades 11-IV acute GVHD). To evaluate the influence of intestinal bacterial decontamination on the development of acute GVHD, patients were classified as being sustained decontaminated if continuous bacterial growth suppression could be shown in the time interval between the day of marrow transplantation and the end points of the analysis. In patients surviving beyond the observation period of microbiologic surveillance, the end point of analysis was day 35. If patients contracted acute GVHD or deceased without acute GVHD before day 35, the respective event times were taken as end points of the analysis. These definitions were applied to the aerobic, the anaerobic, as well as to the entire intestinal bacterial microflora.
Differences between frequencies were compared by the twotailed Fisher's exact test. Estimates of failure times were determined by the product limit method with right-censoring of subjects at the last time point at which they were at risk for a given event. 33 The Mantel-Haenszel test was used for testing the homogeneity of survival functions across ~t r a t a . 3~ To further define their influence on failure times, explanatory variables with a significance level of less than 10% in univariate analysis were included in proportional hazards logistic regression models using forward and backward stepwise selection processes.3s To account for the retrospective nature of the analysis, all explanatory variables were associated with discrete time intervals of the study period before model building. These time intervals were chosen according to changes in major treatment strategies that might have influenced the occurrence of acute GVHD. Changes in major treatment strategies during the study period were the introduction of reverse isolation rooms in 1982 and of CSP-containing regimens in 1986. Depending Microbiologic surveillance.
Srutisticul analysis.
on these three time intervals, an explanatory variable was entered with different values in the logistic regression models. In addition, a three-level time variable corresponding to these time intervals was analyzed as an explanatory variable in the model. To account for the interactions of acute GVHD and intestinal bacterial decontamination, the duration of bacterial growth suppression was defined by a time-dependent covariate function. Bacterial growth suppression took different values at a given time point after transplant depending on whether or not the duration of a patients' decontaminated status exceeded that time interval. Thus, the value of bacterial growth suppression changed for patients in each risk set. Because multiple comparisons were performed, only those explanatory variables with a two-tailed significance level of less than 1% after adjustment for all variables in the model were considered significant. Maximum partial-likelihood estimates and estimates of conditional risk ratios and their 95% confidence intervals (CI) were derived from regression analyses after adjustments for all significant variables in the model^?^,^^ Best subset selection analysis was performed for all significant variables of the proportional hazards regression analysis using the leap and bound algorithm of Furnival and Wilson.38 The criterion used to determine the best model was based on the global score x2 statistic. All analyses were performed on data prospectively collected in the BMT program data base of the University Hospital of Essen.
RESULTS
The overall intestinal bacterial growth suppression achieved in the present study is given in Table 2 . The median bacterial content of fecal samples showed a steep decline 2 weeks after marrow transplantation and remained on a low level until the end of the surveillance period. Complete suppression of bacterial growth, as expressed by the percentage of germ-free fecal samples, was seldom attained during the week before transplantation, but reached up to 65% posttransplant ( Table 3 ). The percentage of completely germ-free samples of patients treated in laminar air flow systems was significantly increased over that of patients in reverse isolation rooms (Table 3) . This also applied to anaerobic bacterial growth suppression, but reached only marginal significance for aerobic bacteria (P = .06) ( Table 3 ). The numbers of patients classified as being sustained decontaminated for the aerobic, the anaerobic, and the entire bacterial microflora were 47 (24%), 41 (21%), and 15 @%), respectively. For Acute G W D . Of the 194 patients. 45 (23%) developed acute GVHD of grades 11-IV at a median of 33 days (range, 15 to 52 days). Significantly less samples from these patients were decontaminated from all bacteria as well as from anaerobic bacteria when compared with the frequency of decontaminated samples from patients with grades 0-1 acute GVHD (Table 3) . sustained growth suppression of anaerobic bacteria was associated with a striking and significant reduction of the cumulative incidence of acute GVHD (P < .OM) (Fig 1) and this resulted from a significant reduction in each target organ involvement with acute GVHD (skin: 8% t 8% v 30% f 8% [ P < .OM]; liver:
Decontamination efficacy.
3% t 3% v 16% t 6% [P < .MI; intestinal tract: 0% v 19% t 6% [P < .W]). In contrast, no significant association between growth suppression of aerobic bactcria and acute GVHD could be dctcctcd (Fig 1) . The same applicd to patients in whom sustaincd growth suppression of the entire bacterial microflora could be demonstrated (Fig 1) . and this was most probably connected to the small number of patients who achieved complete decontamination.
To assess other potentially relevant factors that might have contributed to the development of acute GVHD, categorized features (Table 4) wcrc first tested in univariate analysis. Among these, the underlying discasc had the strongest influcncc on acute GVHD, with a more than 2.5-fold higher cumulative incidcnce for patients with chronic myeloid lcukcmia (CML) as opposcd to othcr disease categories (P < .MMl). Recipients of marrow from a donor of an opposite gender had a higher probability of acute GVHD as compared with sex-matched combinations (P < .03). In male recipients of female donor transplants, the risk of acute GVHD was increased nearly twicc compared with other donor/rccipicnt gender combinations (P < .OM). This was further enhanced by an alloimmu- For personal use only. on September 24, 2017. by guest www.bloodjournal.org From 
NS
Abbreviations: sF, sensitized female marrow donor (by transfusions or pregnancies); standard risk, first remission of acute leukemia, first chronic phase chronic myeloid leukemia, severe aplastic anemia; high risk, advanced malignancies; HSV, herpes simplex virus; VZV, varicella zoster virus; -ve, negative pretransplant herpes virus serology; +ve, positive pretransplant herpes virus serology. *Product-limit estimates (+95% confidence limits).
tsignificance derived from comparisons between strata using the Mantel-*Categorized by age median.
Haenszel test.
nized female donor state (P < .OOl). Pharmacologic immunprophylaxis with CSP-containing regimens decreased the cumulative incidence of acute GVHD as opposed to MTX alone (P < .05). Furthermore, patients nursed in laminar air flow systems tended to have a reduced risk of developing acute GVHD as compared with those treated in reverse isolation rooms (P < .07).
Features with no detectable influence on the risk of acute GVHD in univariate analysis were donor and recipient age (by decades), donor and recipient pretransplant herpes serology, and the stage of the underlying disease ( Table 4) .
The significant features in univariate analysis were then evaluated in a stepwise proportional hazards regression analysis. As indicated in Table 5 , all four explanatory variables found to be significant in univariate analysis model. Using subset selection analysis, the best sequence of the four significant variables selected by the global score criterion was as follows: (1) immunprophylactic regimen; (2) underlying disease; (3) growth suppression of intestinal anaerobic bacteria; and (4) gender matching (global score value, 36.6).
Estimates of acute GVHD stratified by the quality of anaerobic bacterial decontamination were then calculated depending on whether other unfavorable prognostic factors were present. This analysis showed that in patients burdened by at least one of the unfavorable factors, the risk of acute GVHD was reduced by 50% if sustained anaerobic bacterial growth suppression was attained (P < .009) (Fig One hundred fifty of the 194 patients (77%) survived more than 70 days after transplant and were thus eligible for chronic GVHD. With a median onset at day 91 (range, 45 to 555 days), 58 of these patients (39%) contracted clinical symptoms of chronic GVHD, corresponding to a cumulative incidence of 43%. The clinical grades of severity of chronic GVHD were scored as extensive in 35 patients (23%) and as limited in 23 patients (15%), respectively.
Preceding acute GVHD most strongly influenced the development of chronic GVHD (P < .0001). Other signifi-
2).
Chronic G W D . 
<.008
"Maximum partial-likelihood estimates in stepwise proportional hazards regression analysis after adjustment for all covariates in the model. The difference between curves C and D is significant (P e .OM).
cant factors identified by univariate analysis were the underlying disease (P < .mol), the immunprophylactic regimen (P < .0002), the donor/recipient gender combination (P < .003), and the type of protective environment (P < .04). Multivariate analysis, however, confirmed only preceding acute GVHD as an independent predictor for chronic GVHD, with a relative risk estimate of 3.3 (95% CI, 2.3 to 4.6) compared with patients without acute GVHD (P < .0001).
DISCUSSION
This retrospective study was aimed at defining the contribution of growth suppression of the intestinal bacterial microflora on the risk of acute GVHD after clinical sibling marrow transplantation. Nearly identical techniques for protective isolation and intestinal bacterial decontamination, as well as for microbiologic surveillance were used in a predominantly adult patient population over a time period of 13 years, enabling us to accumulate comprehensive data on this topic. Previous clinical trials dealing with the association between the intestinal microflora and acute GVHD generally involved considerably smaller patient numbers as well as differing (eg, pediatric patients, HLAidentical and nonidentical transplant recipients) populat i o n~.~~,~~~~~,~~ Most importantly, these trials were generally focused on this association without adequate statistical evaluation of other contributing factors for this immunpathologic condition.
Sustained complete intestinal bacterial decontamination could only be shown in a small minority of patients in the present analysis, which is in contrast to the higher proportions of successfully decontaminated patients previously reported by other^.^^,^^ However, there are several important distinctions in evaluating the effects of intestinal decontamination between the cited trials, which may explain in part these differences. Among others, these include different regimens of antimicrobial medications, differing observation periods of microbiologic surveillance, and nonuniform definitions of complete decontamination. Microbiologic monitoring did not include culturing of strictly anaerobic bacteria in some trials, while other studies, including this study, analyzed the complete spectrum of intestinal bacteria. Further difficulties in comparing decontamination efficacy result from the generally sparse descriptions of the threshold for detection of bacterial growth in most trials and undefined end points of evaluation in patients contracting acute GVHD. The latter point is of critical importance, because acute GVHD by itself may influence decontamination efficacy due to a reduced ability of affected patients to tolerate the oral antimicrobial medications or by shortened intestinal contact times and lower concentrations of these compounds as a consequence of diarrhea. To allow meaningful comparisons, we therefore considered patients only evaluable for decontamination efficacy until the diagnosis of acute GVHD was established.
The lowest frequencies of decontaminated samples were observed in the immediate pretransplant period, which on the one hand may point to incomplete patient compliance during high-dose radiochemotherapy preceding transplantation or, on the other hand, may indicate that longer time periods before transplantation are required to achieve a decontaminated state. In contrast, 30% to 70% of samples during the posttransplant observation period did not contain detectable numbers of either anaerobic or aerobic bacteria. Whether the increased posttransplant decontamination efficacy reflects better tolerance of the oral antimicrobial medication or other factors adding to the suppression of intestinal bacterial growth, eg, the indispensible administration of systemic antibiotics in severely granulocytopenic patients, was not distinguishable. Using otherwise identical procedures, the decontamination efficacy of patients in laminar air flow systems was higher compared with patients in reverse isolation units. The reasons for this phenomenon remain essentially unknown and deserve further investigation. However, the protective environment alone had no influence on acute GVHD after adjustment for significant factors contributing to this condition.
The key finding in the present analysis was the markedly reduced risk of acute GVHD of grades I1 to IV in patients in whom sustained growth suppression of the anaerobic bacterial microflora was attained. A comparable low incidence of acute GVHD was also observed in the small fraction of completely decontaminated patients. However, this small patient number was insufficient to show a statistically significant advantage with regard to the modulation of acute GVHD opposed to the group of patients that failed to achieve sustained growth suppression of the entire intestinal bacterial microflora. Studies in germ-free or completely decontaminated experimental animals that showed that elimination or complete suppression of the intestinal microflora can abrogate acute For personal use only. on September 24, 2017. by guest www.bloodjournal.org From GVHD even in recipient animals of MHC-mismatched transplants, have stimulated the clinical application of gnotobiologic techniques for the prevention of acute GVHD. [15] [16] [17] [18] [19] However, the biologic basis for this immunmodulatory effect is currently poorly understood. It has been hypothesized that increased lymphokine secretion of phagocytes stimulated by endotoxines or other bacterial products penetrating the intestinal mucosa may lead to a nonspecific activation and polyclonal expansion of graft-derived T lymphocyte^.^^ This, in turn, may promote a specific alloimmune response of donor lymphocytes against nonshared histocompatibility antigens of the recipient tissue. Experimental evidence from studies in rodents also suggests that a specific allorecognition process of donor T lymphocytes may be induced by cross-reactions between intestinal bacterial antigens and antigens of the intestinal mucosal epithelium. 40 In contrast to defined settings in animal studies, the clinical pathogenesis of acute GVHD is superimposed by a variety of predisposing and partially undefined factors, and further depends on treatment strategies such as the type of immunpharmacologic pr~phylaxis.~-l~ To evaluate the effect of intestinal decontamination on a clinical basis, theinultifactorial pathogenesis of this immunpathologic reaction has, therefore, inevitably to be taken into consideration. Using the duration of sustained intestinal bacterial growth suppression as a time-dependent variable, we applied proportional hazards regression analysis techniques with adjustments for other risk factors of acute GVHD and confirmed consistently that decontamination of intestinal anaerobic bacteria independently reduced the probability of acute GVHD. Recent experimental data from a murine transplantation model also support that the anaerobic intestinal microflora has a dominant influence on the occurrence of acute GVHD.39 Whether this is connected to specific properties of anaerobic bacteria currently remains to be defined. However, it can be speculated that complete suppression of the preponderant resident anaerobic microflora in the intestinal lumen, which amounts to greater than 99% of all bacteria, results in a some log higher quantitative reduction of the bacterial load compared with successful decontamination of intestinal aerobic bacteria. These quantitative relationships, in turn, might explain why the proposed interactions between intestinal bacteria and grafted immune cells could be influenced more strongly by anaerobic than by aerobic microorganisms.
With regard to other significant hazards for acute GVHD in the present study, the influence of the underlying disease must be regarded currently as controversial in light of large retrospective analyses from the European and International Bone Marrow Transplant Registries that did not demonstrate an independent association between the underlying disease and acute GVHD.@ The probability of acute GVHD for CML patients in the present study is in good concordance with the majority of reports from single institutions and registry analyse~.l93.~,~J~ In contrast, patients with other underlying diseases showed a comparatively low probability of acute GVHD. This difference was clearly not connected to the age of recipients or donors, because both had no influence on the risk of acute GVHD. Splenectomy did not have to be considered as another potential factor for an increased risk of GVHD in CML patients in the present analysis, because only 3 of the 194 patients underwent splenectomy before transplant.1°J3 Therefore, one has to take other factors into consideration that might explain the effect of the underlying disease on acute GVHD. In this context, a report of the Basel Transplant Group in which a strong association between an increased culture growth of blood-derived macrophages from CML patients and the development of acute GVHD has been described is of interest.4l The investigators postulated that excess macrophages may trigger GVHD in patients with CML by enhancing presentation of recipient antigens to donor T lymphocytes. Further evidence that CML patients might be particularly prone to acute GVHD comes from recent investigations, in which an increased early release of tumor necrosis factor-a (TNF-a) was preferably found in marrow graft recipients with CML (E. Holler, personal communication, and Holler et a142). TNF-a, produced primarily by macrophages, is increasingly recognized as an important mediator of different steps in the pathogenesis of acute GVHD.424 It might be speculated therefore that increased TNF-a levels produced by macrophages of recipients with CML additionally promote the development of acute GVHD and that this pathway is less sensitive to gnotobiotic measures.
The improved prophylactic efficacy of combined CSPcontaining regimens (especially a combination with a short course of MTX) compared with MTX alone has been shown in a prospective randomized trial for patients with severe aplastic anemia and is further supported by retrospective analyses.2JI The effect of female marrow donors for male recipients is in concordance with most reports from single centers and the registrie~.5-~,~,l~,l~ Although we observed the strongest influence in male recipients of transplants from alloimmunized female donors in univariate analysis, multivariate analysis confirmed an independent hazard of female donors for male recipients irrespective of donor alloimmunization.
Patient or donor age were not independent hazards for acute GVHD in the present study. Most other studies examining age as a risk factor failed to show an incremental risk of acute GVHD with increasing age in patients older than 20 y e a r~.~-~.~-~J~ It thus appears justified to assume that the lack of an age-dependent influence on acute GVHD resulted from the small proportion of pediatric and adolescent patients (10%) in the present study. Furthermore, pretransplant herpes virus serology of recipients or marrow donors did not contribute to the risk of GVHD. This is in contrast to some, but not all, retrospective analyses dealing with pretransplant herpes virus serology as a risk factor for GVHD and, therefore, this issue cannot be regarded as precisely defined at
The only independent predictor for chronic GVHD was preceding grades I1 to IV acute GVHD. This is in concordance with a recent report from the International Bone For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Marrow Transplant Registry by Atkinson et al ! 5 However, it might be argued that diminishing the risk of acute GVHD by anaerobic decontamination at the same time prevents the development of (secondary) chronic GVHD.
In conclusion, the present analysis provides for the first time strong evidence that the intestinal anaerobic microflora independently influences the clinical pathogenesis of acute GVHD after allogeneic sibling marrow transplantation and confirms similar observations from experimental animal transplantation models. Antimicrobial chemotherapy specifically targeted to intestinal anaerobic bacteria should therefore be investigated in a prospective trial as an adjunct for the prevention of acute GVHD.
